

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 81687

**Title:** Therapeutic interventions target the NLR inflammasome in ulcerative colitis:  
Comprehensive study

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 04010086

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-11-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-11-21 11:54

**Reviewer performed review:** 2022-11-27 12:08

**Review time:** 6 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous
	Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No

### **SPECIFIC COMMENTS TO AUTHORS**

This manuscript comprehensively reviewed the mechanisms of NLRP3 inflammasome activation by various signals and its regulation and impact on UC, indicating that targeting NLRP3 inflammatory body signals may be a potential candidate drug for treating UC problems. The manuscript is well organized and its presentation is good. The references are complete and the whole article is logical. However, some parts of the manuscript need further modification. 1. The authors tried to list all the phytochemicals and plant extracts, probiotics, synthetic drugs for the treatment of ulcerative colitis targeting NLRP3 inflammatory body signal, which was impossible and would make the manuscript appear too much. The authors should further summarize and simplify this part. 2. I think the discussion parts should be strengthened.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 81687

**Title:** Therapeutic interventions target the NLR inflammasome in ulcerative colitis:  
Comprehensive study

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05393454

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2022-11-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-11-20 14:36

**Reviewer performed review:** 2022-11-28 12:37

**Review time:** 7 Days and 22 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous
	Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No

## SPECIFIC COMMENTS TO AUTHORS

1. There are a few grammatical, alignment and typographical errors are noted in the revised manuscript and it should be carried throughout the manuscript. For example, the words “because of” may be as “because”; “Panax” as “the Panax”; “in ischemic” as “ischemic”; “immuno regulating” as “immune-regulating”; “and others” as “others”; “damp-heat” as “the damp-heat”; “in DSS” as “in the DSS”; “TWHF demonstrate” as “TWHF demonstrates”; “activity mediated” as “activity was mediated”; “such TNF- $\alpha$ ” as “such as TNF- $\alpha$ ”; “, antioxidant [305” as “, and antioxidant [305”; “NLRP3 pathway” as “the NLRP3 pathway”; “NLRP3-inflammasome” as “NLRP3 inflammasome”; “in in a” as “in a”; “in inflammation” as “inflammation”. 2. Check the abbreviations throughout the manuscript and introduce the abbreviation when the full word appears the first time in the abstract and the remaining for the text and then use only the abbreviation (For example, Ulcerative colitis (UC), Inflammatory bowel diseases (IBD), GIT, IL-1 $\beta$ , IL-18, etc.). Make a word abbreviated in the article that is repeated at least three times in the text, not all words need to be abbreviated. 3. The literature search should be described in detail. The authors are encouraged to include the database, search engines (like PubMed, ScienceDirect, Google scholar etc.), the keywords used etc., which may be included in the introduction section or separately in the materials heading since it is a review article. How many articles obtained from each of the search engines? What is the inclusion and exclusion criteria? What is the type of article included in this manuscript? How many articles are included for this manuscript? A diagram depicted the literature search should be included for better understanding and outcome. 4. In the introduction, the authors have cited upto 2019 for the prevalence of disease chosen and it may be



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

updated with recent references. 5. The full form of the species should be given when the first time appears in both the abstract and in the remaining part of the manuscript and it should be followed by only the first letter of the genus (e.g., *Dendrobium officinale* / *Schisandra chinensis* when the first time appears and followed by *D. officinale* / *S. chinensis*, etc.). 6. The figure legends should be improved and a proper footnote should be given. All legends should have enough description for a reader to understand the figure without having to refer back to the main text of the manuscript. For example, the necessary expansion may be given for abbreviations use.